Solid Biosciences Announces Licensing Agreement With Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101 (Globe Newswire)
Solid Biosciences Inc., which acquired UF startup AavantiBio, announced a non-exclusive worldwide license and collaboration agreement with Andelyn Biosciences for the use of Solid’s proprietary, next-generation capsid, AAV-SLB101.
Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003 (BioSpace)
Solid Biosciences Inc., which acquired UF startup AavantiBio, announced that SGT-003, the Company’s investigational gene therapy for Duchenne muscular dystrophy (Duchenne), has been granted an Innovation Passport under the new ILAP.
Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101 (Solid Biosciences)
Solid Biosciences Inc., which acquired UF startup AavantiBio, announced a non-exclusive worldwide license and collaboration agreement with Kinea Bio for the use of Solid’s proprietary, next-generation capsid, AAV-SLB101.
Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Solid Biosciences Inc., which acquired UF startup AavantiBio, announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for SGT-501, the Company’s novel, AAV-based investigational gene therapy for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT).
Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy To Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Solid Biosciences, which acquired UF startup AavantiBio, announced FDA and Health Canada approval to begin clinical trials of SGT-501, a gene therapy targeting CPVT, a severe heart rhythm disorder caused by RYR2 mutations.
Solid Biosciences Reports Positive Initial Clinical Data From Next-Generation Duchenne Gene Therapy Candidate SGT-003
Solid Biosciences Inc., which acquired UF startup AavantiBio, announced positive initial data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy candidate for treating Duchenne muscular dystrophy.
Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
Solid Biosciences Inc., a life sciences company that acquired UF startup AavantiBio, announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for SGT-212, the Company’s, AAV-based gene therapy candidate for the treatment of Friedreich’s ataxia (FA).
Solid Biosciences Announces FDA IND Clearance for First-in-Industry Dual Route of Administration Gene Therapy To Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia
Solid Biosciences Inc., a biotechnology company that acquired UF startup AavantiBio, announced that the U.S. FDA has cleared its Investigational New Drug application for SGT-212 for the treatment of Friedreich’s ataxia.
Solid Biosciences Announces Collaboration With Mayo Clinic To Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies
Solid Biosciences Inc., which acquired UF Startup AavantiBio, has partnered with Mayo Clinic to advance an AAV gene therapy platform for next-generation treatments targeting genetic cardiomyopathies and channelopathies linked to sudden cardiac death.
Solid Biosciences To Present at the Jefferies London Healthcare Conference
Solid Biosciences Inc., a biotechnology company that acquired UF startup AavantiBio, announced that Bo Combo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will present at the Jefferies London Healthcare Conference on November 20.